Antiphospholipid Syndrome with Monoclonal Gammopathy—A Mechanism for Recurrent Thrombosis?

Andrew J. Doyle; Karen A. Breen; Beverley J. Hunt

doi:10.1055/a-1366-9379

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2021; 121(10): 1387-1390
DOI: 10.1055/a-1366-9379

Letter to the Editor

Antiphospholipid Syndrome with Monoclonal Gammopathy—A Mechanism for Recurrent Thrombosis?

Andrew J. Doyle

¹Centre for Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

,

Karen A. Breen

¹Centre for Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

,

Beverley J. Hunt

¹Centre for Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

› Author Affiliations

Abstract

Full Text

References

References
1 Schreiber K, Sciascia S, de Groot PG. et al. Antiphospholipid syndrome. [published correction appears in Nat Rev Dis Primers. 2018 Jan 25;4:18005] Nat Rev Dis Primers 2018; 4: 17103
2 Hisada R, Kato M, Sugawara E. et al. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. J Thromb Haemost 2019; 17 (07) 1134-1143
3 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
4 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332 (15) 993-997
5 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
6 Bazzan M, Vaccarino A, Stella S. et al; Piedmont APS Consortium. Patients with antiphosholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study). Lupus 2016; 25 (05) 479-485
7 Fermand JP, Bridoux F, Dispenzieri A. et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018; 132 (14) 1478-1485
8 Chen LY, Keddie S, Lunn MP. et al. IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. Br J Haematol 2020; 188 (04) 511-515
9 Colović N, Miljić P, Colović M, Milosević-Jovcić N. Multiple M components in two patients with splenic lymphoma with villous lymphocytes. Ann Hematol 2006; 85 (01) 51-54
10 Dührsen U, Paar D, Kölbel C. et al. Lupus anticoagulant associated syndrome in benign and malignant systemic disease–analysis of ten observations. Klin Wochenschr 1987; 65 (18) 852-859
11 von Landenberg P, Schölmerich J, Andreesen R, Vogelhuber M, Lackner KJ. A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody. Rheumatol Int 2002; 22 (03) 129-131
12 Wisløff F, Michaelsen TE, Godal HC. Monoclonal IgM with lupus anticoagulant activity in a case of Waldenström's macroglobulinaemia. Eur J Haematol 1987; 38 (05) 456-460
13 Hara Y, Makita M, Ishikawa T. et al. Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody. Ann Hematol 2013; 92 (04) 563-564
14 Tait RC, Oogarah PK, Houghton JB, Farrand SE, Haeney MR. Waldenström's macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption. J Clin Pathol 1993; 46 (07) 678-680
15 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
16 Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107 (03) 423-429
17 Pengo V, Tripodi A, Reber G. et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
18 Eddou H, Zinebi A, Khalloufi A. et al. Thrombo-haemorrhagic disease-related hypoprothrombinemia-lupus anticoagulant syndrome revealing a light chains multiple myeloma [in French]. J Med Vasc 2018; 43 (05) 325-328
19 Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999; 62 (02) 99-102
20 Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K. A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGlambda-type multiple myeloma. Am J Hematol 2004; 75 (01) 34-39
21 Wu XY, Yin YF, Teng JL, Zhang LW, Yang CD. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report. BMC Immunol 2017; 18 (01) 32
22 Asherson RA, Davidge-Pitts MC, Wypkema E. “Primary” antiphospholipid syndrome evolving into Waldenstrom's macroglobulinaemia: a case report. Clin Rheumatol 2007; 26 (02) 278-280
23 Bellotti V, Gamba G, Merlini G. et al. Study of three patients with monoclonal gammopathies and ‘lupus-like’ anticoagulants. Br J Haematol 1989; 73 (02) 221-227
24 Wisløff F, Sletnes KE, Michaelsen T. Shared idiotypic determinant in mono- and polyclonal anti-phospholipid antibodies with lupus anticoagulant activity. Thromb Res 1991; 61 (03) 201-211
25 Tektonidou MG, Andreoli L, Limper M, Tincani A, Ward MM. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open 2019; 5 (01) e000924
26 Crowley MP, Kevane B, O'Shea SI. et al. Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance. Clin Appl Thromb Hemost 2016; 22 (06) 554-562